Longevity & AgingAlzheimer's Blood Tests and AI Screening Are Reshaping Early Detection
New Alzheimer's therapies only work before symptoms emerge, forcing a race to detect brain pathology years earlier. In the UK, Re:Cognition Health launched CognitionCheck, a £1,295 package combining MRI scans, AI cognitive testing, a specialist consultation, and a p-Tau217 blood biomarker test. Meanwhile, a Nature Communications study validated a Swedish at-home capillary blood sampling device that matches lab-standard venous draws without cold-chain requirements. Together, these developments signal a shift from reactive diagnosis to proactive screening — but highlight a tension between premium clinical pathways and the need for affordable, scalable, decentralized tools that can reach millions of aging adults before cognitive decline sets in.
